Skip to Content


In the US, Defibrotide (defibrotide systemic) is a member of the drug class miscellaneous coagulation modifiers and is used to treat Hepatic Veno-Occlusive Disease.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Therapeutic Category

Anticoagulant agent

Chemical Name

Polydeoxyribonucleotides of bovine lung

Foreign Names

  • Defibrotidum (Latin)
  • Defibrotid (German)
  • Défibrotide (French)
  • Defibrotida (Spanish)

Generic Name

  • Defibrotide (OS: BAN)

Brand Names

  • Defitelio
    Gentium, Lithuania; Gentium, Poland; Gentium, Slovenia; Gentium Spa, France; Gentium Spa, United Kingdom; Gentium Spa, Romania; Gentium Srl, Netherlands; Jazz Pharmaceuticals, Canada; Jazz Pharmaceuticals, United States; Jazz Pharmaceuticals Ireland, Belgium; Sobi, Norway; Sobi, Sweden; Swedish Orphan Biovitrum, Denmark; Swedish Orphan Biovitrum, Finland
  • Defitelio 80mg/ml
    Gentium SpA, Austria; Jazz Pharmaceuticals, Germany
  • Novarid
    Sanofi-Aventis, Italy


BANBritish Approved Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.